

Editorial Manager(tm) for European Journal of Clinical Microbiology & Infectious  
Diseases  
Manuscript Draft

Manuscript Number: EJCMIID-D-10-00039R1

Title: Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia

Article Type: Article

Keywords: pneumococcal pneumonia, cytokines, antibiotic therapy, IL-6, outcome.

Corresponding Author: Dr. Carolina Garcia-Vidal,

Corresponding Author's Institution:

First Author: Susana Padrones

Order of Authors: Susana Padrones; Carolina Garcia-Vidal; Silvia Fernández-Serrano; Ana Fernández; Cristina Masuet; Jordi Carratalà; Mercè Coromines; Carmen Ardanuy; Francesc Gudiol; Frederic Manresa; Jordi Dorca

**Abstract:** Purpose: The aim of this study was to compare the evolution of systemic cytokine levels over time in patients with pneumococcal pneumonia treated either with  $\beta$ -lactam monotherapy or with combination therapy ( $\beta$ -lactam plus fluoroquinolone).

**Methods:** Prospective observational study of hospitalized non-immunocompromised adults with PP. Concentrations of IL-6, IL-8, IL-10 and TNF- $\alpha$  were determined on days 0, 1, 2, 3, 5, and 7. Patients on  $\beta$ -lactam monotherapy were compared with those receiving combination therapy.

**Results:** Fifty-two patients were enrolled in the study. Concentrations of IL-6, IL-8, and IL-10 decreased rapidly in the first days after admission, in accordance with the mean time to defervescence. High levels of IL-6 were found in patients with the worst outcomes, measured by the need for intensive care unit admission and mortality. No major differences in demographic or clinical characteristics or severity of disease were found between patients treated with  $\beta$ -lactam monotherapy or combination therapy. IL-6 levels fell more rapidly in patients with combination therapy in the first 48 hours ( $p=0.016$ ).

**Conclusions:** Our data suggest that systemic expression of IL-6 production in patients with PP is correlated with prognosis. Initial combination antibiotic therapy produces a faster decrease in this cytokine in the first 48 hours.

Response to Reviewers: Professor Nele Jung  
Editor  
European Journal of Clinical Microbiology & Infectious Diseases

Barcelona, April 19th, 2010

REF: EJCMIID-D-10-00039

"Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia"

Dear Professor Jung:

We submitted you the revised manuscript entitled "Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia". We have taken into consideration all the reviewer's suggestions. Please find below a list of responses point by point to the reviewers' comments.

Sincerely,  
Carolina Garcia-Vidal

Infectious Diseases Service. Hospital Universitari de Bellvitge  
Feixa llarga s/n. 08907 L'Hospitalet, Barcelona, Spain  
E-mail: caroglv75@hotmail.com  
Fax: 34 93 2607637

Comments to the Author:

Reviewer #1: Prospective, non randomized study on the evolution and the impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia.

A total of 52 patients enrolled. Data on the evolution of the systemic cytokine levels obtained every 24 hours during the first 5 days and on day 7. In 39 selected patients, the impact of B-lactam alone vs. B-lactam plus fluoroquinolone on the systemic cytokine levels was assessed.

Results showed that high levels of IL-6 at inclusion predicted the worst outcomes, including admission to ICU and mortality. In the group of patients treated with the combination, IL-6 levels fell more rapidly in the first 48 hours.

#### COMMENTS

The study confirms previous reports that have shown a correlation of IL-6 levels at entry and prognosis. The results of the comparative study on the impact of antibiotic therapy showed that combination therapy was associated with a faster decrease in IL-6 in the first 24 and 48 hours of treatment. The Introduction, Methods and Results are appropriate and pertinent information is provided.

In the Discussion, the authors elaborate considerably on the potential advantages of combination vs. monotherapy in CAP and pneumococcal pneumonia. This is unnecessary. First, this issue is not settled and no randomized trials have been performed to answer this question and, second, as the authors themselves acknowledge, they did not intend to determine whether combination therapy had a better impact on survival than monotherapy. In addition, most studies have used the combination of B-lactam plus macrolide, not B-lactam plus fluoroquinolone.

R: According to the reviewer's comment, we have deleted the sentences discussing the potential advantages of combination versus monotherapy. We have added information regarding the point that most studies have used the combination of B-lactam plus macrolide, not B-lactam plus fluoroquinolone (page 20, lines 21 and 22).

Also, they state that the role of fluoroquinolone monotherapy as empirical treatment for severe CAP has not been established. This is not correct. The IDSA/ATS guidelines recommend precisely fluoroquinolone monotherapy as one of the options. Besides, they should not refer to CAP, they should be addressing the issue of pneumococcal pneumonia.

R: To avoid confusion we have deleted the sentence.

## ORIGINAL ARTICLE

**Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia**

**Susana Padrones<sup>1</sup>, Carolina Garcia-Vidal<sup>2,6\*</sup>, Silvia Fernández-Serrano<sup>1</sup>, Ana Fernández<sup>1</sup>, Cristina Masuet<sup>3</sup>, Jordi Carratalà<sup>2,6</sup>, Mercè Coromines<sup>4</sup>, Carmen Ardanuy<sup>5,7</sup>, Francesc Gudiol<sup>2,6</sup>, Frederic Manresa<sup>1</sup>, Jordi Dorca<sup>1,7</sup>**

<sup>1</sup>Respiratory Medicine, <sup>2</sup>Infectious Disease, <sup>3</sup>Preventive Medicine, <sup>4</sup>Immunology, and

<sup>5</sup>Microbiology Departments of Hospital Universitari de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat,

Barcelona, Spain, <sup>6</sup>REIPI (Spanish Network for the Research in Infectious Diseases) and

<sup>7</sup>CIBER de Enfermedades Respiratorias ISCIII, Madrid, Spain

**Corresponding author:** Carolina Garcia-Vidal, MD, Infectious Disease Service, Hospital Universitari de Bellvitge, Feixa Llarga s/n 08907 L'Hospitalet, Barcelona, Spain (carolgv75@hotmail.com); Telephone: 34-932607625; Fax: 34-932607637

**Running title:** Impact of antibiotic therapy on cytokine expression

## ABSTRACT

**Purpose:** The aim of this study was to compare the evolution of systemic cytokine levels over time in patients with pneumococcal pneumonia treated either with  $\beta$ -lactam monotherapy or with combination therapy ( $\beta$ -lactam plus fluoroquinolone).

**Methods:** Prospective observational study of hospitalized non-immunocompromised adults with PP. Concentrations of IL-6, IL-8, IL-10 and TNF- $\alpha$  were determined on days 0, 1, 2, 3, 5, and 7. Patients on  $\beta$ -lactam monotherapy were compared with those receiving combination therapy.

**Results:** Fifty-two patients were enrolled in the study. Concentrations of IL-6, IL-8, and IL-10 decreased rapidly in the first days after admission, in accordance with the mean time to defervescence. High levels of IL-6 were found in patients with the worst outcomes, measured by the need for intensive care unit admission and mortality. No major differences in demographic or clinical characteristics or severity of disease were found between patients treated with  $\beta$ -lactam monotherapy or combination therapy. IL-6 levels fell more rapidly in patients with combination therapy in the first 48 hours ( $p=0.016$ ).

**Conclusions:** Our data suggest that systemic expression of IL-6 production in patients with PP is correlated with prognosis. Initial combination antibiotic therapy produces a faster decrease in this cytokine in the first 48 hours.

**Keywords:** pneumococcal pneumonia, cytokines, antibiotic therapy, IL-6, outcome.

## INTRODUCTION

1  
2 *Streptococcus pneumoniae* remains a major cause of disease worldwide [1]. Among  
3  
4 pneumonia pathogens, it is the most common cause of hospitalization in adults and the  
5  
6 most frequent cause of death [2,3]. Despite improvements in etiologic diagnosis,  
7  
8 effective antibiotic therapy and advances in supportive care, the morbidity and mortality  
9  
10 rates associated with pneumococcal pneumonia (PP) remain high. Case-fatality rates for  
11  
12 bacteremic pneumococcal pneumonia range between 7 and 35% [4].  
13  
14

15  
16 A recent study [5] of the factors associated with early death in patients with community-  
17  
18 acquired pneumonia (CAP) reinforces the classical concept that some deaths are closely  
19  
20 related to inadequate host response [6]. Excessive cytokine response in patients with  
21  
22 severe CAP has been linked with deleterious effects and poor prognosis [7-14].  
23  
24 However, most studies included populations that were heterogeneous in terms of  
25  
26 patients, etiologies, and treatment. Significantly, specific studies of the role of cytokine  
27  
28 response for predicting poor outcomes in patients with PP are scarce. In recent years,  
29  
30 the modulation of the inflammatory response has emerged as a promising concept for  
31  
32 improving the outcomes of CAP. Although it has been suggested that different antibiotic  
33  
34 classes may have different effects on the systemic expression of cytokine production [15-  
35  
36 17], information addressing this issue in PP is lacking.  
37  
38

39  
40 We carried out a prospective study in order to (i) analyze the relationship between  
41  
42 systemic expression of cytokine production and outcomes in patients with PP and (ii)  
43  
44 compare the evolution of systemic cytokine levels over time in patients treated either with  
45  
46  $\beta$ -lactam monotherapy or with combination therapy ( $\beta$ -lactam plus fluoroquinolone).  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

## MATERIAL AND METHODS

**Study subjects and study design.** The study was carried out in a 900-bed university hospital for adults in Barcelona, Spain. The hospital serves an area of 1,100,000 inhabitants and admits approximately 24,000 patients per year. All non-immunocompromised patients with PP who were admitted to the hospital from January 2005 through December 2005 were prospectively recruited and followed up. Patients with neutropenia, HIV infection or transplantation were not included. Concentrations of circulating cytokines were determined for all patients. To assess the effects of treatment on the systemic expression of cytokine production, patients were divided into two groups: those initially treated only with  $\beta$ -lactams ( $\beta$ -lactam group), and those initially treated with combination therapy including  $\beta$ -lactams plus fluoroquinolone (combination therapy group). This prospective longitudinal observational study was approved by the Ethical Committee of our Institution.

**Clinical evaluation and follow-up.** At the initial visit, and before starting empirical antibiotic therapy, patients underwent a complete clinical history, physical examination and laboratory testing. Microbiological studies included two sets of blood cultures and sputum Gram stain and culture when available. Urinary antigen detection for *S. pneumoniae* was performed if indicated by the attending physician. Antimicrobial susceptibility was tested by the microdilution method, following the Clinical Laboratory Standard Institute methods and criteria [18,19].

Empiric antibiotic therapy was administered according to the hospital's guidelines, which recommend the administration of a  $\beta$ -lactam agent (ceftriaxone or amoxicillin-clavulanate) with or without a fluoroquinolone (levofloxacin). Combination therapy was recommended for patients with clinical suspicion of *Legionella* or an atypical pathogen,

1  
2 or in case of severe CAP in the absence of a demonstrative sputum Gram stain.  
3 Levofloxacin monotherapy was allowed for selected cases (i.e., those patients with  
4 allergy to  $\beta$ -lactam agents and no prior quinolone use).  
5

6  
7 Patients were seen daily during their hospital stay by one or more of the investigators  
8  
9 who provided medical advice when requested and recorded demographic  
10  
11 characteristics, underlying disease, clinical features, vaccination status, causative  
12  
13 agents, therapy, and outcomes in a computer-assisted protocol.  
14  
15

16  
17 **Definitions.** PP was diagnosed in patients with signs and symptoms of an acute-onset  
18  
19 lower respiratory tract infection, a new infiltrate on chest radiograph, and one or more  
20  
21 cultures positive for *S. pneumoniae* obtained from blood, normally sterile fluids, or  
22  
23 sputum and/or a positive test for detection of urinary antigen. Only good quality samples  
24  
25 of sputum (<10 squamous epithelial cells and >25 leucocytes per field) were accepted  
26  
27 for processing. *S. pneumoniae* was identified using standard microbiology procedures.  
28  
29 *S. pneumoniae* antigen in urine was detected by using a rapid immunochromatographic  
30  
31 assay (Now<sup>TM</sup>, Binax, Portland, ME, USA).  
32  
33

34  
35 Antimicrobial susceptibility was tested by microdilution. *S. pneumoniae* strains were  
36  
37 serotyped. Molecular characterization was performed by pulsed field gel electrophoresis  
38  
39 after restriction with *Sma*(I) and selected strains were analysed by MLST, as previously  
40  
41 reported [1].  
42  
43  
44

45  
46 The diagnosis of septic shock was based on a systolic blood pressure of less than 90  
47  
48 mmHg and peripheral hypoperfusion with clinical suspicion of uncontrolled infection.  
49  
50 Early death was defined as death due to any cause  $\leq$  48 hours of hospitalization. Overall  
51  
52 mortality was defined as that due to any cause within 30 days of hospitalization. The  
53  
54 severity of illness at presentation was quantified using the validated PORT prediction  
55  
56 rule for 30-day mortality and medical complications in CAP, as described elsewhere [20].  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
**Collection of blood samples and laboratory processing.** For all patients, serial venous blood samples were collected at inclusion, immediately prior to the initiation of antibiotic therapy, and on days 1, 2, 3, 5, and 7. The blood obtained was placed in tubes containing EDTA, immediately centrifugated, and stored at  $-80^{\circ}\text{C}$ . The assays were performed by one of the authors (M.C.), who was blinded to the clinical details of individual patients. The circulating levels of cytokines IL-6, IL-8, IL-10 and TNF- $\alpha$  were measured.

17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
IL-6, IL-8, IL-10 and TNF- $\alpha$ , concentrations were measured using commercially available kits (GENZYME, Cambridge, Mass). The procedure consisted of a solid-phase chemiluminescent immunometric assay. The standards defined in the operator's manual were applied. The limits of detection were 3 pg/ml for IL-6, 1 pg/ml for IL-8, 4 pg/ml IL-10 and 0.5pg/ml for TNF- $\alpha$ .

66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
**Statistical analysis.** To analyze the relationship between systemic expression of cytokine production and the severity of PP we compared serial serum cytokine measurements in patients who had severity markers (bacteremia, ICU admission and mortality) with those who did not. A comparison of serial cytokine measurements was made with the Kruskal-Wallis one-way analysis of variance nonparametric test.

101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
To assess the effects of treatment on the systemic expression of cytokine production, we compared the combination therapy and  $\beta$ -lactam groups. Patients who initially received other antibiotic treatments were excluded. To detect significant differences between groups we used the chi-square test with continuity correction for categorical variables. Normally distributed data were compared by using unpaired  $t$  tests and the Mann-Whitney U-test was used for analysis of variables with non-normal distribution. Studies evaluating serum concentrations of cytokines over time (the fall-down pattern) were performed using the general linear model for repeated-measures tests, considering both



1 within-subject and between-subject factors (differences attributable to antimicrobial  
2 therapy). The contrasts selected were “difference” and “polynomic” for within subject  
3 factors. The analysis was adjusted for potential confounding variables (use of  
4 corticosteroids or ICU admission). The data analyses were performed with SPSS  
5 software version 13.0. In all analyses, we considered P values less than 0.05 to be  
6 statistically significant.  
7  
8  
9  
10  
11  
12  
13

## 14 **RESULTS**

15  
16 **Characteristics of patients and evolution of cytokines over time.** Fifty-two  
17 hospitalized patients with PP were included. Their demographic characteristics and main  
18 clinical features are shown in Table 1. The diagnosis of PP was established with the use  
19 of one or more of the following methods: blood culture (21 cases), sputum Gram stain  
20 and culture (20 cases), urinary antigen test (17 cases), and transthoracic needle  
21 aspiration (2 cases). All *S. pneumoniae* were susceptible to ciprofloxacin (MIC range 0.5-  
22 2 µg/ml) and to levofloxacin (MIC range 0.5-1µg/ml). Using current non-meningeal  
23 breakpoints for beta-lactams, all strains were penicillin (MIC range ≤0.03-2 µg/ml),  
24 amoxicillin (MIC range ≤0.03-2 µg/ml) and cefotaxime (MIC range ≤0.03-1 µg/ml)  
25 susceptible. The most frequent serotypes were 3, 1 and 5, which accounted for 51.4% of  
26 strains. These serotypes were related to ST260 and ST180 for serotype 3, ST306 for  
27 serotype 1.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 Concentrations of all the cytokines studied were detected in peripheral venous blood  
49 samples in all patients, although with a wide range of values. Figure 1 shows the  
50 evolution of cytokines over time. At admission, IL-6 and IL-8 showed the highest values.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 TNF- $\alpha$ , showed a statistically significant trend towards a rapid decrease after 24 to 48h.

2 TNF- $\alpha$  remained basically unmodified throughout the study period.

3  
4  
5 **Clinical outcomes and their relationship with systemic cytokines.** The main  
6  
7 outcomes of patients are summarized in table 2. Mean time to defervescence was 2.19  
8  
9 days (SD 1.19). After the initial evaluation in the emergency department, 37 (71.2%)  
10  
11 patients were admitted to a conventional hospital ward, whereas the other 15 (28.8%)  
12  
13 were transferred to an intensive care unit (ICU). The median length of ICU stay was 7  
14  
15 days (range 2-72 days). The early and overall case-fatality rates were 1.9% and 15.4%  
16  
17 respectively. The evolution of systemic cytokines concentration over time in relation to  
18  
19 bacteremia was determined, as well as ICU admission and mortality. Table 3 shows  
20  
21 serum levels of cytokine on days 0, 1, and 2 in relation to these outcomes. In summary,  
22  
23 no significant differences in cytokine levels were found in patients with or without  
24  
25 bacteremia. IL-6 was significantly higher in patients requiring ICU admission and in  
26  
27 patients who died. High levels of IL-8, especially on day 1, were also documented in  
28  
29 patients with ICU admission and in those who died.  
30  
31

32  
33  
34  
35  
36 On day 0, the third quartile for IL-6 initial concentrations identified 83.3% non-survivors  
37  
38 and only 16.2% survivors. Thus, at admission, an IL-6 level > 5206 pg/ml predicted  
39  
40 mortality with a sensitivity of 100%, a specificity of 79.3%, a positive predictive value of  
41  
42 80.6%, and a negative predictive value of 100%. On day 1, levels of IL-6 > 4097 pg/ml  
43  
44 predicted mortality with a sensitivity of 100%, a specificity of 100%, a positive predictive  
45  
46 value of 80%, and a negative predictive value of 94.3%.

47  
48  
49 **Effects of antibiotic treatment on cytokine production.** To assess the effects of  
50  
51 treatment on systemic cytokine production, we compared 19 patients in the  $\beta$ -lactam  
52  
53 group (ceftriaxone in 15 cases and amoxicillin-clavulanate in four) with 20 patients in the  
54  
55 combination therapy group (ceftriaxone plus levofloxacin in all cases). Thirteen patients  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 (five initially treated with combination therapy [ $\beta$ -lactam plus macrolide], four initially  
2 treated with linezolid and four initially treated with a single fluoroquinolone treatment  
3 were excluded from the analysis. There were no differences in the characteristics of the  
4 patients who were included and those who were excluded. Demographic characteristics,  
5 the main clinical features and outcomes of patients by treatment group are shown in  
6 Table 4. Interestingly, no important differences in demographic characteristics,  
7 vaccination status, time from pneumonia onset to inclusion, previous use of steroids,  
8 statins, non-steroidal anti-inflammatory drugs, severity of infection, bacteremia and  
9 outcomes were found between groups. Chronic heart and cerebrovascular diseases  
10 were more frequent in patients in the  $\beta$ -lactam group. Conversely, the presence of  
11 multilobar infiltrates was more frequent in the combination therapy group.

12 As shown in figure 2, the IL-6 decrease was more rapid in the combination therapy  
13 group, particularly in the first days ( $p=0.016$ ). TNF- $\alpha$  levels were lower in the combination  
14 therapy group, but the differences did not reach statistical significance. No differences in  
15 the evolution over time of IL-8 were detected. Conversely, levels of anti-inflammatory  
16 cytokines (IL-10) remained higher ( $p<0.001$ ) in the combination therapy group. All these  
17 differences remained significant after adjustment for the use of corticosteroids and ICU  
18 admission.

## 19 **DISCUSSION**

20 Previous studies of CAP have noted that most cytokines can be detected in systemic  
21 circulation and show a significant pattern of decline in the first hours of treatment.  
22 Indeed, all cytokines studied in the present report were detected in venous blood  
23 samples in patients with PP at hospital admission. Thus, most patients developed a  
24 systemic extension of the initially compartmentalized immune response in the lung.

1 Interestingly, all these cytokines, except for TNF- $\alpha$ , declined in the first 48 hours. These  
2 decreases correlate clinically with the time to clinical defervescence.  
3

4 Previous studies have reported that an excess of proinflammatory cytokines is  
5 associated with poor prognosis of CAP [7-14]. Our results showed a similar relationship  
6 between high levels of cytokines and poor outcomes in the specific population with PP.  
7 We demonstrated that levels of IL-6 on admission, as well as levels of IL-6 and IL-8 in the  
8 first 48h, were the best markers for predicting poor outcomes, in agreement with  
9 previous studies analyzing any etiology of CAP. A recent study<sup>11</sup> found that the addition  
10 of biological markers such as C-reactive protein to severity scoring systems (PSI, CURB-  
11 65 and CRB-65) improves the 30-day mortality prediction. Further studies are currently  
12 needed to establish the potential role of IL-6 and IL-8 in supplementing prognosis scoring  
13 systems in order to achieve a more accurate identification of patients with a greater  
14 probability of death.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 The most notable finding of this study was the difference in the cytokine profile between  
32 patients treated with  $\beta$ -lactam monotherapy and those treated with combination therapy.  
33 We found that combination therapy of a  $\beta$ -lactam plus fluoroquinolone produced a faster  
34 decreased in IL-6 in the initial 48 hours of treatment in patients with PP. Taking into  
35 account the relationship between IL-6 and poor prognosis for PP, the modulation of the  
36 expression of this cytokine may be a key point for improving patient outcomes. Whether  
37 combination therapy can improve outcomes in patients with CAP is a controversial issue  
38 [21-26]. Moreover, most studies have used the combination of  $\beta$ -lactam plus macrolide,  
39 not  $\beta$ -lactam plus fluoroquinolone.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

54 A possible explanation for the differences observed in the pattern of systemic cytokine  
55 production over time is that  $\beta$ -lactam cell wall activity causes the release of cell wall  
56 components which act as potent inflammatory inducers [27-30]. One hypothesis is that  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 combination therapy offers more rapid microbial killing due to the presence of quinolones  
2 and hence shortens the exposure of the host to microbial products. Additionally,  
3  
4 fluoroquinolones have an intrinsic immunomodulation effect that inhibits the production of  
5  
6 certain pro-inflammatory cytokines [15-18,31]. The possible beneficial effects of  
7  
8 fluoroquinolones on the systemic expression of cytokine response when combined with  
9  
10  $\beta$ -lactam therapy in patients with PP have not been previously explored, but our results  
11  
12 suggest that their potential anti-inflammatory and immunomodulatory effects persist  
13  
14 when combined with  $\beta$ -lactam. A previous study [8] explored the effects of  
15  
16 fluoroquinolone monotherapy in modulating the cytokine response in patients with PP,  
17  
18 finding that it achieved a faster decrease in serum TNF- $\alpha$  production at 120 hours post-  
19  
20 admission than  $\beta$ -lactam monotherapy.  
21  
22  
23  
24  
25  
26

27 Our study has limitations that should be acknowledged. First, the study was  
28  
29 observational and included a relatively small number of patients. Second, only four  
30  
31 patients were treated with fluoroquinolone monotherapy, precluding comparisons in the  
32  
33 pattern of systemic expression of cytokine production. Finally, it should be emphasized  
34  
35 that our aim was not to establish whether combination therapy of  $\beta$ -lactam plus  
36  
37 fluoroquinolone has a clear impact on survival in the first hours after admission for PP.  
38  
39 Therefore, our results should be interpreted with caution.  
40  
41  
42  
43

44 We found that IL-6, IL-8, IL-10 were detected in venous blood samples in all patients with  
45  
46 PP at hospital admission with a rapid decrease in the first 48h, correlating with clinical  
47  
48 defervescence. High levels of IL-6 were found in patients with the worst outcomes. Initial  
49  
50  $\beta$ -lactam and fluoroquinolone combination antibiotic therapy produced a faster decrease  
51  
52 of this cytokine in the first 48 hours.  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## **Funding**

This study was supported by research grants of Fundació Pi i Sunyer; FUCAP (Fundació Catalana de Pneumologia); REIPI RD06/0008 from the Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III, Spanish Network for the Research in Infectious Diseases; by FIS (070864); and by Institut d'Investigació Biomèdica de Bellvitge (Dr. Garcia-Vidal).

## **Transparency declaration**

None to declare

## References

- 1  
2 [1] Ardanuy C, Tubau F, Pallarés R, et al. (2009) Epidemiology of invasive  
3 pneumococcal disease among adult patients in Barcelona before and after pediatric 7-  
4 valent pneumococcal conjugate vaccine introduction 1997-2007. Clin Infect Dis 48:57-  
5 64.  
6  
7  
8  
9  
10  
11 [2] Barlett JG, Mundy L.M. (1995) Community-acquired pneumonia. N Engl J Med  
12 333:1618-24.  
13  
14  
15  
16 [3] Rosón B, Carratalà J, Dorca J, et al. (2001) Etiology, reasons for hospitalization, risk  
17 classes and outcomes of patients with community-acquired pneumonia hospitalized on  
18 the basis of conventional admission criteria. Clin Infect Dis 33:158-65.  
19  
20  
21  
22  
23 [4] Feikin DR, Schuchat A, Kolczak M. (2000) Mortality from invasive pneumococcal  
24 pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 90:223-9.  
25  
26  
27  
28 [5] Garcia-Vidal C, Fernández-Sabé N, Carratalà J, et al. (2008) Early mortality in  
29 patients with community-acquired pneumonia: causes, and risk factors. Eur Respir J  
30 32:733-9.  
31  
32  
33  
34  
35 [6] Austrian R, Gold J. (1964) Pneumococcal bacteremia with especial reference to  
36 bacteremic pneumococcal pneumonia. Ann Intern Med 60:759-70.  
37  
38  
39  
40 [7] Antunes G., Evans SA, Lordan JL, et al. (2002) Systemic cytokine levels in  
41 community-acquired pneumonia and their association with disease severity. Eur Respir J  
42 20:990-5.  
43  
44  
45  
46  
47 [8] Calbo E, Alsina M, Rodríguez-Carballeira M, et al. (2008) Systemic expression of  
48 cytokine production in patients with severe pneumococcal pneumonia: effects of  
49 treatment with a  $\beta$ -lactam versus a fluoroquinolone. Antimicrob Agents Chemother  
50 52:2359-402.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- [9] Fernández-Serrano S, Dorca J, Coromines M, et al. (2003) Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. *Clin Diag Lab Immunol* 10:813-20.
- [10] Kellum JA, Kong L, Fink MP, et al. (2007) Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory markers of sepsis (GenIMS) study. *Arch Intern Med* 167:1655-63.
- [11] Menendez R, Martinez R, Reyes S, et al. (2009) Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. *Thorax* 64:587-91.
- [12] Monton C, Torres A, El-Ebiary M, et al. (1999) Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. *Crit Care Med* 27:1745-53.
- [13] Örtqvist A, Hedlund J, Wretling B, et al. (1995) Diagnostic and prognostic value of Interleukin-6 and C-reactive protein in community-acquired pneumonia. *Scand J Infect Dis* 27:457-62.
- [14] Xu F, Droemann D, Rupp J, et al. (2008) Modulation of the inflammatory response to *Streptococcus pneumoniae* in a model of acute lung tissue infection. *Am J Respir Cell Mol Biol* 39:522-9.
- [15] Demartini G, Esposti D, Marthyn P, et al. (2004) Effect of multiple doses of clarithromycin and amoxicillin on IL-6, IFN $\gamma$  and IL-10 plasma levels in patients with community-acquired pneumonia. *J Chemother* 16:82-5.
- [16] Choi J., Song M, Kim G, et al. (2003) Effect of moxifloxacin on production of proinflammatory cytokines from human peripheral blood mononuclear cells. *Antimicrob Agents Chemother* 47:3704-7.
- [17] Dalhoff A, Shalit I. (2003) Immunomodulatory effect of quinolones. *Lancet Infect Dis* 3:359-71.



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- [18] Clinical Laboratory Standard Institute (CLSI). Performance standards for antimicrobial susceptibility testing: 19th informational supplement. CLSI document M100-S18. Wayne, PA: CLSI, 2009.
- [19] Clinical and Laboratory Standard Institute (CLSI). Methods for dilution antimicrobial susceptibility test for bacteria that growth aerobically; approved standard: 7th edition. CLSI document M7-A6. Wayne, PA: CLSI, 2006.
- [20] Fine MJ, Auble TE, Yealy DM, et al. (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. *N Engl J Med* 336:243-50.
- [21] Waterer GW, Somes GW, Wunderink RG. (2001) Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. *Arch Intern Med* 161:1837-42.
- [22] Martinez JA, Horcajada JP, Almela M, et al. (2003) Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. *Clin Infect Dis* 36:389-95.
- [23] Baddour LM, Yu VL, Klugman KP, et al. (2004) Combination therapy lowers mortality among severely ill patients with pneumococcal pneumonia. *Am J Respir Crit Care Med* 170:440-4.
- [24] Rodriguez A., Mendia A, Sirvent JM, et al. (2007) Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. *Crit Care Med* 35:1493-8.
- [25] Harbarth S., Garbino J, Pugin J, et al. (2005) Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. *Eur J Clin Microbiol Infect Dis* 24:688-90.
- [26] Aspa J, Rajas O, Rodriguez de Castro F, et al. (2006) Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. *Eur Resp J* 27:1010-9.

1 [27] Heumann D, Barras C, Severin A, et al. (1994) Gram-positive cell wall stimulates  
2 synthesis of tumor necrosis factor alpha and interleukin 6 by human monocytes. Infect  
3 Immun 62:2715-21.  
4

5  
6 [28] Tomasz A, Saukkonen D. (1989) The nature of cell wall derived inflammatory  
7 components of pneumococci. Pediatr Infect Dis J 8:902-3.  
8

9  
10 [29] Tuomanen E, Rich R, Zak O. (1987) Induction of pulmonary inflammation by  
11 components of the pneumococcal cell surface. Am Rev Respir Dis 1987;135:869-74.  
12

13 [30] Tuomanen E, Vanholder R, De Paepe P, et al. (1996) Immunomodulating effects of  
14 antibiotics: literature review. Infection 24:275-91.  
15

16 [31] Blaine T, Pollice P, Rosier R, et al. (1997) Modulation of the production of cytokines  
17 in titanium-stimulated human peripheral blood monocytes by pharmacological agents:  
18 the role of camp-mediated signaling mechanism. J Bone Joint Surg 79:1519-28.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Table 1. Demographic characteristics and the main clinical features of patients**


| <b>Characteristic</b>                  | <b>All patients</b> |          |
|--|---------------------|----------|
|  | <b>N=52</b>         | <b>%</b> |
| <b>Demographics</b>                    |                     |          |
| Age, mean years (SD)                   | 58.8 (19.3)         |          |
| Male, sex                              | 34                  | 65.4     |
| Current smoker                         | 21                  | 40.4     |
| Heavy drinking                         | 4                   | 7.7      |
| <b>Vaccination status</b>              |                     |          |
| Influenza vaccine (season)             | 11                  | 21.2     |
| Pneumococcal vaccination <sup>e</sup>  | 4                   | 7.7      |
| <b>Underlying disease</b>              |                     |          |
| COPD <sup>f</sup>                      | 14                  | 26.9     |
| Chronic heart disease                  | 10                  | 19.2     |
| Diabetes mellitus                      | 9                   | 17.3     |
| Cerebrovascular disease                | 4                   | 7.7      |
| Chronic liver disease                  | 1                   | 1.9      |
| Chronic renal disease                  | 0                   | 0        |
| Time from pneumonia onset to inclusion | 2 (0-15)            |          |
| Previous use of statins                | 6                   | 11.5     |
| Concomitant use of steroids            | 2                   | 3.8      |
| Concomitant use of NSAID* drugs        | 5                   | 9.6      |
| <b>High risk PSI (IV-V)</b>            | 31                  | 59.6     |
| <b>Clinical features</b>               |                     |          |

|  |               |      |
|--|---------------|------|
| Altered mental status on admission                       | 11            | 21.1 |
| Renal failure (Cr > 150 mmol/L)                          | 15            | 28.8 |
| Urea median mmol/dl (range)                              | 9.5 (2-30)    |      |
| Heart rate mean (SD)                                     | 104.5 (19.20) |      |
| Respiratory rate mean (SD)                               | 33.5 (9.6)    |      |
| Temperature median (range)                               | 38.5 (36-40)  |      |
| Leucocytes mean (SD)                                     | 14431 (7406)  |      |
| PO <sub>2</sub> /fiO <sub>2</sub> <sup>f</sup> mean (SD) | 243 (43.8)    |      |
| PO <sub>2</sub> /fiO <sub>2</sub> <sup>f</sup> < 300     | 43            | 82.7 |
| Multilobar infiltrates                                   | 24            | 46.2 |
| Shock at admission                                       | 7             | 13.5 |
| Pleural effusion   | 12            | 23.1 |

\*nonsteroidal anti-inflammatory drug

1 **Figure 1. Sequential cytokine levels in patients with severe pneumococcal pneumonia.**

2  
3 **All cytokines except TNF- $\alpha$ , showed a statistically significant trend towards a rapid**  
4 **decrease after 24**  
5  
6



**Table 2. Outcomes of pneumococcal pneumonia of patients hospitalized for community-acquired pneumonia.**

| Outcomes  | All         |      |
|---|-------------|------|
|   | n =52       | %    |
| Bacteremia                                      | 21          | 36.8 |
| ICU admission                                   | 15          | 29   |
| Length of ICU admission median (range)          | 5.5 (2- 72) |      |
| Need for mechanical ventilation                 | 9           | 17.3 |
| Non-invasive mechanical ventilation             | 3           | 5.7  |
| Invasive mechanical ventilation                 | 6           | 11.5 |
| Mechanical ventilation-free days median (range) | 6.5 (2- 72) |      |
| Early mortality                                 | 1           | 1.9  |
| Overall mortality                               | 8           | 15.4 |

**Table 3. Results of cytokines on days 0 and 1 in the groups with or without bacteremia, with or without ICU admission and deaths or survivors.**

| Cytokine                       | Bacteremia                                |  |           | ICU admission                             |  |                 | Mortality  |  |                 |
|--------------------------------|---|--|-----------|---|--|-----------------|--|--|-----------------|
|                                | No (n=31)<br>Median (P <sub>25</sub> -75) | Yes (n=21)<br>Median (P <sub>25</sub> -75) | p         | No (n=37)<br>Median (P <sub>25</sub> -75) | Yes (n=15)<br>Median (P <sub>25</sub> -75) | p               | Survivors (n=46)<br>Median (P <sub>25</sub> -75) | Deaths (n=8)<br>Median (P <sub>25</sub> -75) | p               |
| <b>Day 0</b>                   |   |  |           |   |  |                 |  |  |                 |
| <b>IL-6</b>                    | 2945<br>(919-4550)                        | 2700<br>(778-10335)                        | <b>NS</b> | 1890<br>(850-4488)                        | 10335<br>(2700-21160)                      | <b>.028</b>     | 2190<br>(835-4492)                               | 8878<br>(6236-18453)                         | <b>.020</b>     |
| <b>IL-8</b>                    | 181<br>(67-307)                           | 152<br>(43-975)                            | <b>NS</b> | 165<br>(54-256)                           | 452<br>(43-1675)                           | <b>NS</b>       | 180<br>(51-392)                                  | 148<br>(48-5953)                             | <b>NS</b>       |
| <b>IL-10</b>                   | 23<br>(13-84)                             | 32<br>(9-60)                               | <b>NS</b> | 20<br>(2-63)                              | 47<br>(29-207)                             | <b>NS</b>       | 26<br>(13-64)                                    | 91<br>(12-259)                               | <b>NS</b>       |
| <b>TNF-<math>\alpha</math></b> | 3<br>(0.2-9.5)                            | 13<br>(0-19)                               | <b>NS</b> | 3<br>(0-10)                               | 12<br>(2-19)                               | <b>NS</b>       | 3<br>(0-11)                                      | 11<br>(4-17)                                 | <b>NS</b>       |
| <b>Day 1</b>                   |   |  |           |   |  |                 |  |  |                 |
| <b>IL-6</b>                    | 276<br>(99-1146)                          | 753<br>(234-2375)                          | <b>NS</b> | 237<br>(99-848)                           | 2700<br>(1405-16029)                       | <b>&lt;.001</b> | 276<br>(107-850)                                 | 8992<br>(2347-21518)                         | <b>&lt;.001</b> |
| <b>IL-8</b>                    | 62<br>(19-229)                            | 39<br>(16-164)                             | <b>NS</b> | 36<br>(15-76)                             | 288<br>(176-837)                           | <b>&lt;.001</b> | 41<br>(19-165)                                   | 217<br>(55-1689)                             | <b>.050</b>     |
| <b>IL-10</b>                   | 12<br>(3-19)                              | 10<br>(14-73)                              | <b>NS</b> | 11<br>(4-19)                              | 51<br>(5-203)                              | <b>NS</b>       | 11<br>(3-19)                                     | 66<br>(3-232)                                | <b>NS</b>       |
| <b>TNF-<math>\alpha</math></b> | 3<br>(0-5)                                | 11<br>(1.2-15)                             | <b>NS</b> | 3<br>(0-11)                               | 5<br>(0.5-11)                              | <b>NS</b>       | 3<br>(0-12)                                      | 6<br>(0-19)                                  | <b>NS</b>       |
| <b>Day 2</b>                   |   |  |           |   |  |                 |  |  |                 |
| <b>IL-6</b>                    | 94<br>(24-217)                            | 87<br>(66-458)                             | <b>NS</b> | 66<br>(24-112)                            | 308<br>(118-1626)                          | <b>&lt;.001</b> | 85<br>(30-228)                                   | 2522<br>(1091-5246)                          | <b>.001</b>     |
| <b>IL-8</b>                    | 24<br>(9-76)                              | 22<br>(3-39)                               | <b>NS</b> | 20<br>(9-54)                              | 54<br>(2-92)                               | <b>NS</b>       | 20<br>(6-59)                                     | 66<br>(30-508)                               | <b>NS</b>       |
| <b>IL-10</b>                   | 7<br>(0-13)                               | 7<br>(0-25)                                | <b>NS</b> | 7<br>(0-13)                               | 9<br>(3-65)                                | <b>NS</b>       | 7<br>(0-12)                                      | 38<br>(0-104)                                | <b>NS</b>       |
| <b>TNF-<math>\alpha</math></b> | 2<br>(0-9)                                | 10<br>(2-16.4)                             | <b>NS</b> | 2<br>(0-13)                               | 6<br>(2-12)                                | <b>NS</b>       | 3<br>(0-12)                                      | 2<br>(0-15)                                  | <b>NS</b>       |

**Table 4. Demographic characteristics, main clinical features and outcomes of patients by treatment group.**

| <b>Characteristic</b>                  | <b>β-lactams<br/>group<br/>N= 19</b> |      | <b>Combination<br/>therapy group<br/>N= 20</b> |      | <b>p</b> |
|--|--------------------------------------|------|--|------|----------|
| <b>Demographics</b>                    |                                      |      |  |      |          |
| Age, median years (range)              | 63.3 (18.0)                          |      | 56.5 (17.0)                                    |      | .232     |
| Male, sex                              | 14                                   | 73.7 | 12   | 60   | .501     |
| Current smoker                         | 6                                    | 31.6 | 9  | 47.4 | .508     |
| Heavy drinking                         | 3                                    | 15.8 | 1  | 5    | .287     |
| <b>Vaccination status</b>              |                                      |      |  |      |          |
| Influenza vaccine (season)             | 4                                    | 21.0 | 5  | 25.0 | .317     |
| Pneumococcal vaccination <sup>e</sup>  | 1                                    | 5.2  | 3  | 15.0 | .699     |
| <b>Underlying disease</b>              |                                      |      |  |      |          |
| COPD <sup>f</sup>                      | 7                                    | 36.8 | 4  | 20.0 | .160     |
| Chronic heart disease                  | 9                                    | 47.4 | 0  | 0    | <.001    |
| Diabetes mellitus                      | 4                                    | 21.1 | 3  | 15.0 | .451     |
| Cerebrovascular disease                | 3                                    | 15.8 | 0  | 0    | .036     |
| Chronic liver disease                  | 1                                    | 5.3  | 0  | 0    | .241     |
| Chronic renal disease                  | 0                                    | 0    | 0  | 0    | 1        |
| Time from pneumonia onset to inclusion | 2.5 (0-15)                           |      | 3 (1-15)                                       |      | .975     |
| Previous use of statins                | 3                                    | 15.8 | 2  | 10.0 | .661     |
| Concomitant use of steroids            | 2                                    | 10.5 | 0  | 0    | .230     |
| Concomitant use of NSAID* drugs        | 3                                    | 15.8 | 0  | 0    | .106     |
| <b>High risk PSI (IV-V)</b>            | 13                                   | 68.4 | 14   | 70   | 1        |



| <b>Clinical features</b>                                 |                  |      |              |      |        |
|--|------------------|------|--------------|------|--------|
| Altered mental status on admission                       | 4                | 21.0 | 3            | 15.0 | .451   |
| Renal failure (Cr > 150 mmol/L)                          | 8                | 42.1 | 5            | 25.0 | .320   |
| Urea median mmol/dl (range)                              | 11 (2-30)        |      | 11 (5-25)    |      | .538   |
| Respiratory rate mean (SD)                               | 31.9 (8.3)       |      | 36.9 (9.1)   |      | .123   |
| Temperature median (range)                               | 38.5 (37.7-38.2) |      | 38.5 (36-40) |      | .813   |
| PO <sub>2</sub> /fiO <sub>2</sub> <sup>f</sup> mean (SD) | 238.0 (43.0)     |      | 232.6 (42.6) |      | .760   |
| PO <sub>2</sub> /fiO <sub>2</sub> <sup>f</sup> < 300     | 16               | 84.2 | 18           | 90   | .146   |
| Multilobar infiltrates                                   | 2                | 10.5 | 18           | 90   | <0.001 |
| Shock at admission                                       | 3                | 15.8 | 3            | 15.0 | .408   |
| Pleural effusion   | 3                | 15.8 | 5            | 25.0 | .727   |
| <b>Bacteremia</b>  | 8                | 42.1 | 6            | 30.0 | .325   |
| <b>Outcomes</b>  |                  |      |              |      |        |
| ICU admission  | 6                | 31.6 | 6            | 30.0 | 1      |
| Need for mechanical ventilation                          | 3                | 15.8 | 4            | 20.0 | .732   |
| Early mortality  | 1                | 5.3  | 0            | 0    | .299   |
| Overall mortality  | 3                | 15.8 | 5            | 25.0 | .694   |

\*nonsteroidal anti-inflammatory drugs

1 **Figure 2. Evolution of IL-6 and Il-10 systemic concentrations by treatment group. IL-6**  
2 **decreased faster in the combination therapy group (p=0.016). Conversely, levels of**  
3 **anti-inflammatory cytokines were higher in this group (p <0.001). This analysis has**  
4 **been adjusted for potential confounder variables (i.e. the use of corticosteroids or ICU**  
5 **admission)**  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17

